LearnGlossaryMarketStocksSuperinvestorsSign in

QURE

uniQure N.V.

Healthcare · $1.8B market cap

Verdict

We can't put a fair value on QURE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth4.6% a year✗
Sales growth14.4% a year✓
Free cash flow growth—?
Return on invested capital-32.3%✗

Follow QURE

Track it on your watchlist and see the full analysis. Free.

Create a free account

Superinvestors

1 of the investors we track holds QURE. In Q2 2026, 1 added. Who we track

Lee Ainslie

Maverick Capital · as of Q2 2026

$42.6M

925,383 shares

Moves in Q2 2026

Added: Lee Ainslie

About uniQure N.V.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works